TipRanks
Advertisement
Advertisement

CH:UUD Stock Latest News

Syntara Issues New Unquoted Performance Rights Under Employee Incentive Plan
Company AnnouncementsSyntara Issues New Unquoted Performance Rights Under Employee Incentive Plan
5d ago
Syntara Issues 34.9 Million Unquoted Performance Rights Under Incentive Scheme
PremiumCompany Announcements
Syntara Issues 34.9 Million Unquoted Performance Rights Under Incentive Scheme
5d ago
Syntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy
PremiumCompany Announcements
Syntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy
9d ago
Syntara boosts R&D funding with A$4.7m tax incentive
PremiumCompany Announcements
Syntara boosts R&D funding with A$4.7m tax incentive
19d ago
Syntara Seeks ASX Quotation for 1.5 Million New Shares
PremiumCompany Announcements
Syntara Seeks ASX Quotation for 1.5 Million New Shares
25d ago
Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline
PremiumCompany AnnouncementsSyntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline
25d ago
Syntara Loss Widens as Revenue Falls and Asset Base Shrinks
Premium
Company Announcements
Syntara Loss Widens as Revenue Falls and Asset Base Shrinks
1M ago
Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar
Premium
Company Announcements
Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar
2M ago
Syntara secures FDA backing and funding as key clinical programs advance
PremiumCompany Announcements
Syntara secures FDA backing and funding as key clinical programs advance
2M ago
Syntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder
PremiumCompany Announcements
Syntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder
3M ago
Syntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial
PremiumCompany Announcements
Syntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial
3M ago
Syntara Shares Halted Ahead of Key Parkinson’s Trial Update
PremiumCompany Announcements
Syntara Shares Halted Ahead of Key Parkinson’s Trial Update
3M ago
Syntara Issues 1.75 Million Unquoted Performance Rights Under Incentive Scheme
PremiumCompany AnnouncementsSyntara Issues 1.75 Million Unquoted Performance Rights Under Incentive Scheme
3M ago
Syntara Limited Seeks ASX Quotation for Additional Shares
Premium
Company Announcements
Syntara Limited Seeks ASX Quotation for Additional Shares
3M ago
Syntara Shifts CEO Pay Toward Long-Term Equity Incentives
Premium
Company Announcements
Syntara Shifts CEO Pay Toward Long-Term Equity Incentives
3M ago
Syntara advances scar therapy trials as Phase 1b recruitment passes halfway mark
PremiumCompany Announcements
Syntara advances scar therapy trials as Phase 1b recruitment passes halfway mark
3M ago
Syntara Completes Second Tranche of A$8m Share Placement
PremiumCompany Announcements
Syntara Completes Second Tranche of A$8m Share Placement
4M ago
Syntara Seeks ASX Quotation for 53.7 Million New Shares
PremiumCompany Announcements
Syntara Seeks ASX Quotation for 53.7 Million New Shares
4M ago
Syntara Wins Shareholder Backing for Capital Resolutions to Fund Drug Pipeline
PremiumCompany Announcements
Syntara Wins Shareholder Backing for Capital Resolutions to Fund Drug Pipeline
4M ago
Syntara Secures A$8.84m to Extend Runway and Advance Drug Pipeline
PremiumCompany AnnouncementsSyntara Secures A$8.84m to Extend Runway and Advance Drug Pipeline
4M ago
Syntara to Brief Investors on Key Parkinson’s Trial Ahead of Phase 2 Data
Premium
Company Announcements
Syntara to Brief Investors on Key Parkinson’s Trial Ahead of Phase 2 Data
4M ago
D&A Holdings diluted in Syntara fundraise but commits to second tranche
Premium
Company Announcements
D&A Holdings diluted in Syntara fundraise but commits to second tranche
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >